Evidence map›Paper›PMID 41888511›Full record

ArticleCell death discovery2026

FKBP5 isoforms shape immune pathways related to tumor tolerance.

Simona Romano, Laura Marrone, Gennaro Acanfora, Valeria Di Giacomo, Marialuisa Alessandra Vecchione, Elena Vigliar, Antonino Iaccarino, Nicola Russo, Emanuele Sasso, Guendalina Froechlich and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Simona RomanoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy. simona.romano@unina.it.ORCID http://orcid.org/0000-0002-9401-5814
Laura MarroneDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Gennaro AcanforaDepartment of Public Health, Federico II University, Naples, Italy.
Valeria Di GiacomoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Marialuisa Alessandra VecchioneDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Elena VigliarDepartment of Public Health, Federico II University, Naples, Italy.
Antonino IaccarinoDepartment of Public Health, Federico II University, Naples, Italy.
Nicola RussoAnimal Models Core Facility Biogem s.c.a.r.l, Ariano Irpino (AV), Italy.
Emanuele SassoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Guendalina FroechlichDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Massimiliano CacaceCentro Servizi Veterinari, Federico II University, Naples, Italy.
Chiara MalasommaDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Rosetta AbateDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Simona CaggianoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Federica AracriDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Yichuan XiaoCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0001-7804-6971
Giancarlo TronconeDepartment of Public Health, Federico II University, Naples, Italy.
Tommaso RussoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy.
Maria Fiammetta RomanoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy. mariafiammetta.romano@unina.it.ORCID http://orcid.org/0000-0001-5557-7307

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FKBP51 is a multifunctional immunophilin that regulates key cellular pathways, including NF-κB signaling, AKT activation, and steroid receptor trafficking. Alternative splicing of the FKBP5 gene generates a shorter isoform, FKBP51s, lacking the C-terminal TPR domain mediating protein‒protein interactions. Previous studies support the hypothesis that splicing of the FKBP5 gene underpins the mechanisms crucial for establishing control over T lymphocyte expansion and that the balance between the canonical and spliced isoforms could be pivotal in the immune system's capacity to finely tune the intensity and span of the immune response.To investigate the impact of FKBP51 splicing, we generated a knock-in mouse model (huFKBP5) expressing only the full-length human FKBP51 isoform, thereby ablating all splice variants. While the heterozygous animals were viable and fertile, the homozygous huFKBP5

Identifiers

PMID41888511
PMCPMC13184302

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.